Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
3.182
+0.062 (1.99%)
At close: Apr 28, 2026, 4:00 PM EDT
3.200
+0.018 (0.57%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Lisata Therapeutics Employees
Lisata Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 5 or -19.23% compared to the previous year.
Employees
21
Change (1Y)
-5
Growth (1Y)
-19.23%
Revenue / Employee
$8,095
Profits / Employee
-$789,810
Market Cap
28.90M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| Kyntra Bio | 34 |
| Daré Bioscience | 24 |
| BriaCell Therapeutics | 16 |
| Lantern Pharma | 16 |
| Apollomics | 13 |
| Tvardi Therapeutics | 12 |
| Neuphoria Therapeutics | 8 |
LSTA News
- 7 weeks ago - Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewsWire
- 3 months ago - Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - GlobeNewsWire
- 3 months ago - Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - GlobeNewsWire
- 6 months ago - Lisata Therapeutics Earnings Call Transcript: Q3 2025 - Transcripts
- 6 months ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 6 months ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 6 months ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire